Abstract-We aimed to evaluate the consequences of the 2017 pediatric hypertension definitions, compared with the 2004 pediatric hypertension definitions on the prevalence of hypertension and to assess the performance of these 2 sets of guidelines in predicting adult hypertension, metabolic syndrome, and left ventricular hypertrophy (LVH). This longitudinal study consisted of 3940 children (47% male; ages 3-18 years) who came from the Bogalusa Heart Study with 36-year follow-up since childhood. Hypertension was identified in 7% and 11% as defined in the 2004 and 2017 guidelines, respectively. The 2004 and 2017 guidelines demonstrated similar associations with adulthood hypertension, metabolic syndrome, and LVH. However, the proportion of children identified as having hypertension who developed adult LVH increased from 12% when defined by the 2004 guidelines to 19% when defined by the 2017 guidelines. Overall, the 329 (8%) children who were reclassified to higher blood pressure categories by the 2017 guidelines were more likely than their propensity score-matched normotensive counterparts to develop hypertension, metabolic syndrome, and LVH in later life, whereas 38 (1%) children who were reclassified to lower blood pressure categories by the 2017 guidelines had similar cardiometabolic outcomes to their propensity score-matched normotensive counterparts. Hence, children who were reclassified to higher blood pressure categories based on 2017 guidelines were at increased risk of developing hypertension, metabolic syndrome, and LVH in later life. The 2017 guidelines identified a group of children with adverse metabolic profile and cardiometabolic outcomes, whose cardiovascular risk seemed to be underestimated using the 2004 guidelines.
I
n August 2017, a new guideline for the diagnosis and management of elevated blood pressure (BP) in children was jointly published by the American Academy of Pediatrics (AAP) and endorsed by the American Heart Association. 1, 2 This guideline is an update from the fourth report of the National Institutes of Health's National Heart, Lung, and Blood Institute (NIH/NHLBI) published in 2004. 3 Studies linking BP levels in childhood with heightened risk for subsequent adverse cardiovascular outcomes are required to better appraise the value of these new BP thresholds. Furthermore, before these new BP thresholds are adopted as the basis for identifying children at high risk of cardiovascular disease (CVD), it is necessary to answer the following crucial questions: Do the additional children whose BP levels were reclassified upward (those who are newly defined as having elevated BP or new-onset hypertension or are assigned a more advanced stage under the 2017 AAP guidelines) indeed have adverse cardiometabolic outcomes? What are the cardiometabolic outcomes of the children whose BP is newly assigned to a lower level by the 2017 AAP guidelines compared with the 2004 NIH/NHLBI guidelines?
The aim of this study was, therefore, to directly compare the ability of the 2004 NIH/NHLBI guidelines and the new 2017 AAP guidelines to predict cardiometabolic outcomes, including hypertension, metabolic syndrome (MetS), and subclinical CVD later in life with the use of data from the longitudinal cohort of the BHS (Bogalusa Heart Study). As a secondary aim, we evaluated CVD risk profile and cardiometabolic outcomes among children whose BP levels were reclassified upward and whose BP levels were reclassified downward under the 2017 guidelines compared with the 2004 NIH/NHLBI report.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Cohort
The BHS is a series of long-term studies begun in 1973 focusing on understanding the early natural history of CVD since childhood. 4 Between 1973 and 2016, 9 cross-sectional surveys of children aged 3 to 18 years and 11 surveys of adults aged 19 to 58 years, who had been previously examined as children were conducted in the semirural biracial (65% white and 35% black) community of Bogalusa, Louisiana. This panel design of repeated cross-sectional examinations conducted approximately every 3 to 4 years resulted in serial observations from childhood to adulthood. A total of 3940 children (2523 whites and 1417 blacks; 47% male; ages 3-18 years at baseline) had been examined for BP at least once in childhood (baseline) and at least once in adulthood (follow-up) were included in the analysis exploring which guidelines better predicted progression to adulthood hypertension. Among those participants, 3437 adults (45% men; ages 19-57 years at follow-up) had measures of waist circumference, systolic/diastolic BP, total cholesterol (TC), triglyceride, LDL-C (low-density lipoprotein cholesterol) and HDL-C (high-density lipoprotein cholesterol), and fasting plasma glucose and thus could be included in the analysis exploring which guidelines better predicted the development of MetS in adulthood. Of the 3940 children, 1760 (44% male; ages 24-57 years at follow-up) had adult echocardiography conducted between 2000 and 2016 to measure left ventricular hypertrophy (LVH) and were included in the analysis exploring which guidelines better-predicted progression to LVH. There was no difference in the baseline characteristics between children who had and did not have adult echocardiography measurements (Table S1 in the online-only Data Supplement)
Written informed consent was obtained from parents or guardians in childhood and from the participants themselves in adulthood. Study protocols were approved by the Institutional Review Board of the Tulane University Health Sciences Center.
Clinical Measurements
Standardized protocols were followed by trained and certified personnel across all surveys. Participants were instructed to fast for 12 hours before the screening. For each participant, replicate measurements of height and weight were obtained, and the mean values were used for analysis. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Waist circumference in adults was measured midway between the rib cage and the superior border of the iliac crest twice to the nearest 0.1 cm by a nonstretchable tape, and the mean value was used in analysis. BP was measured between 8:00 am and 10:00 am on the right arm with appropriate cuff in a relaxed sitting position by 2 trained technicians (triplicate each), using calibrated mercury sphygmomanometers. The 6 readings were averaged. For both children and adults, the first Korotkoff phase was used for systolic BP; the fifth Korotkoff (K5) phase was used for diastolic BP. Diastolic BP at the fourth Korotkoff (K4) phase was also recorded for all children. For children with the K5 being very low (<20 mm Hg), the K4 was used as diastolic BP. 
Biochemical Laboratory Measurements
Between 1973 and 1986, TC and triglyceride were determined with Technicon Auto Analyzer II (Technicon Instrument Corp, Tarrytown, NY) according to the laboratory manual of the Lipid Research Clinics Program. From 1987, these variables were measured using an Abbott VP instrument (Abbott Laboratories, Abbott Park, Ill) by enzymatic procedures. 5, 6 Both chemical and enzymatic procedures met the performance requirements of the Lipid Standardization Program of the Centers for Disease Control and Prevention. Measurements on Centers for Disease Control and Prevention-assigned quality control samples showed no consistent bias over time within or between surveys. Serum lipoprotein cholesterols were analyzed by using a combination of heparin-calcium precipitation and agar-agarose gel electrophoresis procedures. 7 Between 1978 and 1991, fasting plasma glucose was determined with a glucose oxidase method using a Beckman glucose analyzer (Beckman Instruments, Fullerton, CA). Since 1992, fasting plasma glucose has been measured enzymatically as part of a multichemistry profile.
Echocardiography
Left ventricular mass (LVM) was measured by 2-dimensional M-mode echocardiography with 2.25-and 3.5-MHz transducers following American Society of Echocardiography recommendations. 8 Parasternal long-and short-axis views were used for measuring LV end-diastolic and end-systolic measurements in duplicate, and the mean was calculated. LV mass was calculated from a necropsy-validated formula on the basis of a thick-wall prolate ellipsoidal geometry. 9 The index of LVM to height 2.7 (g/m 2.7 ; LVM index) was used to adjust for body size.
Statistical Analysis
For both the 2004 NIH/NHLBI 3 and the 2017 AAP references, 1 age-, sex-, and height-specific systolic/diastolic BP percentiles were calculated. We assessed elevated BP and hypertension status in children per (Table S3 ). In adulthood, participants were classified as having hypertension if they had systolic BP ≥130 mm Hg, diastolic BP ≥80 mm Hg, or with self-reported treatment of hypertension with antihypertensive medication according to the 2017 American College of Cardiology/American Heart Association guidelines on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines. 11 We also performed a sensitivity analysis using adult hypertension definition according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 12 MetS was defined according to the consensus criteria in 2009 13 as the presence of ≥3 of the following criteria: elevated waist circumference; triglyceride ≥150 mg/dL; HDL-C <40 mg/dL in men and <50 mg/dL in women; BP ≥130/85 mm Hg or on antihypertensive drug treatment in a patient with a history of hypertension; or fasting plasma glucose ≥100 mg/dL. LVH was defined as LVM index >46.7 g/m 2.7 in women and >49.2 g/m 2.7 in men.
14 All statistical analyses were performed with SAS version 9.2 (SAS Institute, Inc, Cary, NC). Age-and sex-specific Z scores were calculated for childhood height using Lambda Mu Sigma tables from the Centers for Disease Control and Prevention. 15 These height Z scores were then converted to age-and sex-specific height percentiles. The differences in baseline and follow-up variables between groups were tested using generalized linear models (for continuous) and χ 2 or Fisher exact tests (for categorical). The kappa (κ) statistic was calculated to assess agreement in BP categorization as defined in the 2017 AAP guidelines and the 2004 NIH/NHLBI guidelines.
Poisson regression models with robust errors variance were used to examine the ability of the 2017 AAP guidelines and the 2004 NIH/NHLBI guidelines in predicting adult hypertension, MetS, and LVH, with adjustment for age, sex, race, childhood BMI, and length of follow-up. For individuals who participated in multiple baseline or follow-up surveys, we used those measures that provided the longest time period between baseline and follow-up. We also used receiver operating characteristic curve analysis to determine the performance of these 2 guidelines in predicting adult hypertension, MetS, and LVH.
Children whose BP readings were reclassified to a higher level under the 2017 guidelines in comparison with the 2004 NIH/NHLBI guidelines were considered reclassified upward and treated as cases. One-to-one propensity score matching by age, sex, height percentile, and length of follow-up resulted in the inclusion of 329 pair of participants (cases and children with normal BP based on both sets of guidelines). Continuous variables of these 2 groups were analyzed with the paired-sample Student t test. Differences for categorical variables were compared using McNemar test. Standardized differences of matched pairs were also used to assess the balance of the covariates that were included in the propensity score model. Conditional logistical regression models were used to examine the relationship between reclassifications (case status) and development of adult health outcomes including hypertension, MetS, and LVH. The process was repeated for the children whose BP levels were reclassified downward under the 2017 guidelines compared with the 2004 NIH/NHLBI guidelines. Significance was accepted at a 2-tailed P <0.05.
Results
Characteristics of participants with normal BP, elevated BP, and hypertension, as classified by the 2 sets of guidelines, are presented in Table 1 . Overall, children with elevated BP or hypertension were more likely to be boys, black, and obese as compared to normotensive children. Likewise, more of those individuals classified as having elevated BP or hypertension in childhood went on to develop hypertension, MetS, and LVH in adulthood.
Using the 2017 AAP BP tables, the mean systolic BP percentile of all participants was higher (50) Overall, 329 children were reclassified upward under the 2017 guidelines compared with the 2004 report (Table 3) To better characterize the CVD risk profile and cardiometabolic outcomes, the 329 children whose BP levels were reclassified upward under the 2017 guidelines were compared with propensity score-matched children who were classified as normotensive by both sets of guidelines. Covariates that were included in the propensity score model were balanced between the 2 groups (Table S4) . Those children with reclassified upward BP levels had significantly higher baseline BMI, TC, lower follow-up HDL-C, and higher LVM index (all P<0.05; Table 4 ). In addition, they experienced a higher prevalence of hypertension, MetS, and LVH at follow-up. For the outcome of adult hypertension of the propensity score-matched pairs, the odds ratio (95% CI) was 2.37 (1.67-3.35) for children whose BP levels were reclassified upward as compared to normotensive children (Table 5 ). For the outcome of adult MetS and LVH, the corresponding figures were 1.50 (1.07-2.31) Values are mean±SDs. BMI indicates body mass index; BP, blood pressure; DBP, diastolic BP; FPG, fasting plasma glucose; HDL-C high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVH, left ventricular hypertrophy; LVMI, left ventricular mass index; MetS, metabolic syndrome; SBP, systolic BP; TC, total cholesterol; TG, triglycerides; and WC, waist circumference. *P value for difference between group1 and group 2. †P value for difference between group1 and group 3. ‡P value for difference between group2 and group 3.
and 2.18 (1.23-3.88), respectively. Because risks of cardiometabolic outcomes might be contributed by increased BMI and TC levels, which clustered with increased BP, we further compared the cardiometabolic outcomes of propensity score-matched pairs after adjusting for BMI and TC. The risks of adult hypertension, MetS, and LVH for the children whose BP values were reclassified upward slightly changed but remained still statistically significant (Table 5) . Additionally, we compared the cardiometabolic outcomes of propensity score-matched pairs after excluding overweight and obese children (Table 5) . One-to-one propensity score matching by age, sex, height percentile, BMI, TC, and length of follow-up resulted in the inclusion of 197 pair of participants (children whose BP readings were reclassified upward and children with normal BP). Compared with normotensive children, those with BP readings reclassified upward experienced higher risk of adult hypertension and MetS. There was no significant difference in risk of LVH (Table S5) . CVD risk profile and cardiometabolic outcomes among the 38 children whose BP levels were reclassified downward under the 2017 guidelines were also compared with propensity score-matched controls. The groups differed in none of any anthropometric and biochemical measures (Table S6) . These children whose BP values were reclassified downward did not experience increased risks for adult hypertension, MetS, or LVH (Table S7 ).
The area under the receiver operating characteristic curves for detection of adult hypertension, MetS, and LVH increased incrementally under the 2017 guidelines, although the increases are not statistically significant (Table  S8) . It is important to note that childhood hypertension assessed by 2004 and 2017 guidelines preceded LVH in 12% (44) and 19% (67) of incident cases of LVH, respectively (Table S9) (Tables S10  and S11 ).
The optimal cut points for systolic/diastolic BP values in different age groups based on associations with adult hypertension were presented in Table S12 .
In the sensitivity analysis, the results were similar when adult hypertension was defined by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure criteria (Tables S13 and S14) .
Discussion
In the current study, despite the similar strengths of associations and overall predictive performance, as compared to the 2004 guidelines, the 2017 guidelines detected more children with hypertension, and more of these hypertensive children developed cardiometabolic outcomes including hypertension, MetS, and LVH in adulthood. For example, among those who went on to develop LVH in adulthood, the proportion with childhood hypertension increased from 12% under the 2004 guidelines to 19% under the 2017 guidelines. Children reclassified to more advanced levels of abnormal BP based on the 2017 guidelines had more unfavorable CVD risk characteristics and experienced higher risks for adult hypertension, MetS, and LVH compared with their propensity score-matched normotensive children. Our results also show that those children reclassified to lower levels have similar anthropometric and biochemical characteristics and cardiometabolic outcomes to normotensive children. These findings have important health implications and support that the new BP thresholds are justifiable. All analyses were adjusted for race, sex, age, childhood body mass index, and length of follow-up. LVH indicates left ventricular hypertrophy; MetS, metabolic syndrome; NIH/NHLBI, National Institutes of Health's National Heart, Lung, and Blood Institute; and RR, relative risk. The values are numbers of individual participants in the Bogalusa Heart Study. BP indicates blood pressure; and NIH/NHLBI, National Institutes of Health's National Heart, Lung, and Blood Institute.
BP thresholds for elevated BP and hypertension in childhood are primarily based on the statistical distribution of BP levels rather than linking childhood BP levels to CVD outcomes in later life. 16, 17 The 2017 guidelines make a prominent change in childhood BP categorization, the establishment of absolute BP thresholds that were the same cut points used in the new 2017 adult guidelines on BP classification 18 for defining elevated BP, stage 1, and stage 2 hypertension for children ≥13 years old. The choice of adult cut points is primarily based on the predictive value of BP for CVD outcomes. 19 However, to our knowledge, there are no other studies to date assessing the ability of the 2017 pediatric hypertension categories to predict subclinical CVD outcomes in adulthood. The current study is unique in that it followed individuals from childhood to adulthood and assessed the performance of BP categories according to 2017 guidelines in prediction of adult outcomes of adult hypertension, MetS, and LVH.
In our study, the 2017 guidelines identified a group of children who were more likely than their propensity scorematched normotensive pairs to be obese and hypercholesterolemic (elevated TC) at their baseline examination. It is known that childhood obesity is associated with an unfavorable cardiometabolic profile 20 and is a predictor for future CVD incidence and all-cause mortality. 21 Like obesity, childhood elevated TC may have its own effect on BP or reflect a common cause associated with increased BP levels or the individual's lifestyle. 22 A recent cross-sectional study showed that those children reclassified upward under the 2017 guidelines were more obese and had higher LDL-C levels compared with normotensive children. 23 In the current longitudinal study, we observed that the children who were reclassified upward were at increased risk of developing adult hypertension, MetS, and LVH even after adjusting for BMI and TC. Furthermore, in normal weight children, those with BP readings reclassified upward still experienced higher risks of adult hypertension and MetS. Taken together, it seems that the 2017 guidelines identify a group of high-risk children with cardiometabolic outcomes, whose CVD risk was underestimated when using the 2004 guidelines. It is recommended that using BP levels in conjunction with other CVD risk factors to guide the recommendation to initiate treatment has the potential to prevent more CVD events and may be cost-effective. 18 Given that childhood BP, BMI, and TC were key contributors to CVD health, 24 the 2017 guideline may contribute to risk stratification in clinical decision making for children whose BP levels were reclassified upward and encourage more involved diagnostic evaluations and lifestyle modification. However, children whose BP levels were reclassified upward based on 2017 guidelines might not develop CVD events. Longitudinal studies of CVD morbidity and mortality will ultimately be needed to precisely evaluate the effect of the 2017 guidelines on CVD outcomes, which will further refine the BP guidelines for children.
Our study also showed that implementing the 2017 guidelines may reclassify some children to lower BP categories (38, 1%) who would otherwise be assigned to higher categories by the 2004 criteria. A notable finding from our study was the lack of significant differences in cardiometabolic outcome between the children who were reclassified downward under the 2017 guidelines and those propensity score-matched normotensive children. On the basis of these findings, it would seem that the children who were reclassified downward may not require additional evaluation.
The strength of our study includes a well-characterized cohort with extended follow-up and with echocardiography examination, BP readings measured by the criterion standard of auscultation, LVM assessed according to recommendations in both sets of guidelines, and detailed anthropometric and laboratory measures from childhood to adulthood. In addition, this study is one of the first to explore cardiometabolic outcomes among children whose BP levels were reclassified under the 2017 guidelines.
Limitations of the present study require careful consideration. First, it may be underpowered to properly evaluate the differences in metabolic profile and cardiometabolic outcomes between children who were reclassified to a different BP category compared with those normotensive children because of insufficient numbers. For instance, the odds ratio for adult hypertension was 1.62 (0.61-4.32) for those down classified-it was not significant, but this may be because of small numbers (n=38). Second, given the community-based sample, extrapolating results to the whole of the United States should be cautious. Finally, major CVD events in adulthood, such as coronary heart disease and stroke, were not available in the data. Nevertheless, subclinical outcomes, such as LVH and MetS, and CVDs like hypertension are strongly predictive of later life major CVD events.
Perspectives
We demonstrated that the 2017 guidelines increased hypertension prevalence as a result of reclassification to higher BP categories. Although the 2004 and 2017 guidelines were similar in overall ability to predict adult hypertension, MetS, and LVH, using the 2017 guidelines improved the sensitivity of childhood hypertension in predicting future development of LVH in adulthood. Implementing the 2017 guidelines would identify a group of children who were reclassified upward with newly diagnosed elevated BP or a worsening stage of hypertension with adverse metabolic profile and increased risks of progression to adult hypertension, MetS, and LVH.
